Originally published In Press as doi:10.1074/jbc.M102347200 on October 26, 2001
J. Biol. Chem., Vol. 277, Issue 2, 984-992, January 11, 2002
T-tubule Depolarization-induced Local Events in the Ryanodine
Receptor, as Monitored with the Fluorescent Conformational Probe
Incorporated by Mediation of Peptide A*
Takeshi
Yamamoto
and
Noriaki
Ikemoto
§¶
From the
Boston Biomedical Research Institute,
Watertown, Massachusetts 02472 and § Department of
Neurology, Harvard Medical School,
Boston, Massachusetts 02115
Received for publication, March 15, 2001, and in revised form, October 15, 2001
 |
ABSTRACT |
There is a considerable controversy about the
postulated role of the Thr671-Leu690
(peptide A) region of the dihydropyridine (DHP) receptor
1 II-III loop. Here we report that peptide A introduced the fluorescence probe
methyl coumarin acetamido (MCA) in a well defined region of the
ryanodine receptor (RyR), A-site, in a specific manner. Depolarization
of the T-tubule moiety of the triad induced a rapid increase of the
fluorescence intensity of the MCA attached to the A-site. Other RyR
agonists, which activate the RyR without mediation of the DHP receptor
(e.g. caffeine, polylysine, and peptide A), induced
Ca2+ release without producing such an MCA fluorescence
increase. Both magnitudes of the fluorescence change and
Ca2+ release increased with the increase in the degree of
T-tubule depolarization. MCA fluorescence increase at the A-site and
subsequent sarcoplasmic reticulum Ca2+ release were blocked
by blocking of the DHP receptor-to-RyR communication. These results may
be accounted for by two alternative models as follows. (a)
Upon T-tubule depolarization a portion of the DHP receptor comes close
to the RyR, forming a hydrophobic interface (within such an interface
the A-site is located), or (b) T-tubule depolarization may produce a
local conformational change in the A-site-containing region of the RyR
that is not necessarily within the DHP receptor/RyR junction.
 |
INTRODUCTION |
The concept that one of the cytoplasmic loops of the
DHP1 receptor
1 subunit
(II-III loop) plays a critical role in skeletal muscle-type E-C
coupling emerged from an earlier finding of Tanabe et al.
(1, 2) that replacement of the II-III loop of the cardiac DHP receptor
with the skeletal muscle-type sequence conferred the skeletal
muscle-type E-C coupling activity in dysgenic myotubes expressing
chimeric DHP receptors. According to further studies with chimeras (3),
replacement of the Phe725-Pro742 region of the
II-III loop from the cardiac to the skeletal sequence conferred the
skeletal type E-C coupling, leading to the proposal that the critical
functions required for the skeletal-type E-C coupling are localized in
this region (the so-called "determinant"). It was also shown that
the skeletal Leu720-Leu764 region (which is
approximately identical to our peptide C described below and that
contains the determinant region) rescued both skeletal-type orthograde
and retrograde communications between the DHP receptor and the RyR (4).
In support of the concept that the II-III loop plays the critical role
in E-C coupling, a recombinant peptide corresponding to the II-III loop
in fact activated the RyR Ca2+ channel in the in
vitro system (5).
Further studies with shorter peptides suggested that the important
functions of E-C coupling are localized in the two different regions of
the loop. Namely, the peptides corresponding to the overlapping regions
encompassing residues Glu666-Glu726 (6) and
Thr671-Leu690 (peptide A, Refs. 7-11)
produced a strong activation of the RyR. This suggests that the
putative activator of E-C coupling may reside in the peptide A region,
although whether the critical activating function is localized in the
Arg681-Leu690 region (peptide A-10, Ref. 12)
or in the Thr671-Glu680 region (13) has not
yet been settled. Interestingly, peptide C corresponding to the
Glu724-Pro760 region of the II-III loop (note
that this is essentially identical to the
Leu720-Leu764 sequence containing the
determinant region described above) inhibited peptide A-mediated
activation of the RyR (7, 14) and also produced a moderate inhibition
of depolarization-induced tension development in the skinned muscle
fiber (15). These results led us to our recent proposal that the
voltage-dependent activation and blocking (re-priming)
processes of skeletal-type E-C coupling are mediated by alternative
binding of the peptide A and the peptide C regions of the II-III loop
to the RyR, respectively (14, 16). According to the more recent
studies, peptide C (7, 14) and its slightly extended version
corresponding to the Leu720-Gln765region (13)
activate the RyR under certain conditions, suggesting that peptide C
can perform either activating or inhibitory function depending upon the conditions.
The above view that the peptide A region plays an important role in the
activation process of E-C coupling has been questioned by several
investigators. According to Proenza et al. (17), a moderate
degree of scrambling of the amino acid sequence in the peptide A-10
region (see above) produced no detectable changes in E-C coupling in
the dysgenic myotubes, although the same scrambling produced a severe
loss of the activating function of peptide A-10 in case of the in
vitro experiments (12). Furthermore, according to Wilkens et
al. (18) replacement of the Leu720-Leu764
region of the housefly II-III loop, which has the sequence structure highly dissimilar to the skeletal muscle
1S II-III loop,
with the skeletal muscle sequence-restored skeletal muscle-type E-C coupling. Furthermore, according to the more recent report of Ahern
et al. (19) deletion of the
Thr671-Leu690 peptide A region from the
1
subunit produced virtually no effect on Ca2+ conductance,
charge movement, and Ca2+ transients. Thus, the in
vivo evidence accumulated so far is inconsistent with the view
that the peptide A region may play an active role in the in
vivo E-C coupling.
To test the physiological significance of the information obtained from
the in vitro studies with peptide A, we addressed in this
study two key questions as follows. (a) Do these II-III loop
peptides, peptide A and peptide C, bind to the RyR in a site-specific manner? (b) Can the fluorescence probe that is attached to
the peptide A-binding site or to the peptide C-binding site report the
local events that are relevant to the physiological coupling between
the DHP receptor and the RyR? As shown in our recent publications (12,
14, 20, 21), the fluorescence conformational probe, MCA, can be
incorporated into the designated site on the RyR in a site-specific
manner using an appropriate RyR-specific ligand (e.g. the
channel blocker, neomycin (14, 20), and an agonist of the RyR,
polylysine (21)) as a site-directing carrier. Here we report that the
site-directed fluorescence labeling technique using peptide A as a
site-directing carrier permitted us to introduce the MCA probe into the
160-kDa segment at the C-terminal side of the amino acid residue 1400 of the RyR, indicating that peptide A binds to this region of the RyR
in a specific manner. Furthermore, depolarization of the T-tubule
moiety of the triad, but not any of chemical/pharmacological agonists
of the RyR, produced a rapid increase in the fluorescence intensity of
the MCA attached to the peptide A-binding site. The magnitude of the
depolarization-induced Ca2+ release was approximately
proportional to that of the MCA fluorescence change as determined at
various degrees of T-tubule depolarization. Inhibition of T-tubule
depolarization and T-tubule-to-RyR signal transmission resulted in the
inhibition of both MCA fluorescence change and Ca2+
release. Various agonists of the RyR other than T-tubule
depolarization, such as caffeine, polylysine, and peptide A, induced
Ca2+ release but did not produce any appreciable change in
the MCA fluorescence. These results suggest that depolarization in the T-tubule produces dramatic changes either in the DHP receptor/RyR interface or in the cytoplasmic domain of the RyR or both. It is
tempting to speculate that the site of peptide A-mediated MCA labeling
is localized in the DHP receptor/RyR-interacting interface, but an
alternative possibility cannot be excluded that the MCA labeling site
is localized in the non-junctional cytoplasmic region of the RyR
(cf. Fig. 7 models).
 |
EXPERIMENTAL PROCEDURES |
Preparation--
Triad-enriched microsomal fractions were
prepared from the rabbit back paraspinous and hind leg skeletal muscles
by a method of differential centrifugation as described previously
(22). Microsomes from the final centrifugation were homogenized in a sample solution containing 0.3 M sucrose, 0.15 M potassium gluconate, proteolytic enzyme inhibitors (0.1 mM phenylmethanesulfonyl fluoride, 1 µg/ml leupeptin, 2.0 µg/ml soybean trypsin inhibitor), 20 mM MES, pH 6.8, to a
final concentration of 20-30 mg/ml, frozen immediately in liquid
N2, and stored at
78 °C.
Peptides Used and Peptide Synthesis--
We used two peptides,
peptide A and peptide C, corresponding to the
Thr671-Leu690 and
Glu724-Pro760 regions of the II-III loop of
the DHP receptor
1 subunit of the rabbit skeletal muscle,
respectively (7). The peptides were synthesized on an Applied
Biosystems model 431A synthesizer employing Fmoc
(N-(9-fluorenyl)methoxycarbonyl) as the
-amino-protecting group. The peptides were cleaved and de-protected with 95%
trifluoroacetic acid and purified by reversed-phase high pressure
liquid chromatography.
Reagents Used--
Anti-RyR polyclonal antibody was kindly
provided by Dr. Kevin P. Campbell. Anti-residue 416, anti-residue 1417, anti-residue 2727 antibodies were kindly provided by Dr. Susan L. Hamilton. Anti-residue 5029 antibody was kindly provided by Dr. Andrew
R. Marks. [3H]Ryanodine was purchased from PerkinElmer
Life Sciences. Recombinant calpain II was purchased from
Calbiochem. Sulfosuccinimidyl
3-((2-(7-azido-4-methylcoumarin-3-acetamido)ethyl)dithio) propionate
(SAED) was from Pierce.
Site-specific MCA Labeling of the Peptide A- and Peptide
C-binding Site of the RyR--
Site-specific fluorescent labeling of
the peptide A- and peptide C-binding sites of the RyR moiety of the
triad was performed using the cleavable hetero-bifunctional
cross-linking reagent SAED (21) in the following way. First,
peptide-SAED conjugates were formed by incubating 0.5 mM
peptide with 0.5 mM SAED in 20 mM HEPES, pH
7.5, for 60 min at 22 °C in the dark. Both peptide A-SAED and
peptide C-SAED conjugates retained essentially the same activities as
those of the unmodified peptides. The reaction was quenched by 20 mM lysine. Free SAED was removed using Sephadex G15 gel
filtration. The peptide-SAED conjugate (5 µM final
concentration) was mixed with 2 mg/ml triad protein in the sample
solution (see "Preparation" under "Experimental Procedures")
containing 1 mM BAPTA/calcium buffer (1.0 µM
free Ca2+) in the dark, and the mixture was incubated at
4 °C for about 5 min to ensure the access of the peptide-SAED
conjugate to the peptide-binding sites. The incubation time of 5 min
seemed to be sufficient to introduce the peptide-SAED conjugated to its target site located in the junctional triad, as judged from the fact
that this incubation time was sufficient to produce a maximal MCA
labeling and a maximal MCA fluorescence response upon T-tubule depolarization. Then, the mixture was photolysed with UV light in a
Pyrex tube at 4 °C for 2 min.
-Mercaptoethanol was added (100 mM final concentration) to cleave the disulfide bond of
SAED. After incubation on ice for 1 h, the mixture was centrifuged
at 100,000 × g for 15 min, and the sedimented vesicles
were re-suspended in the sample solution to a final protein
concentration of ~20 mg/ml. Gels containing electrophoretically
separated protein bands were illuminated with a 360-nm UV lamp through
the UG-1 filter (Schott), and the fluorescence images were obtained
with a digital camera (Olympus C-2020) using a 440-nm interference
filter with 40-nm bandwidth.
Proteolytic Cleavage of the RyR Polypeptide Chain--
For
digestion with calpain II, fluorescently labeled microsomes (1 mg/ml)
were mixed with recombinant calpain II at the ratio of 6 units of
calpain to 1 mg of SR protein in a solution containing 150 mM NaCl and 20 mM MOPS, pH 7.2. Digestion was
started by adding 3 mM CaCl2. After the
digestion for 6 min at 22 °C, the reaction was stopped by adding 3 mM BAPTA.
For digestion with trypsin, fluorescently labeled microsomes (1 mg/ml)
were mixed with L-1-tosylamido-2-phenylethyl chloromethyl ketone trypsin at the protein/trypsin ratios of 4000:1, 2000:1, 1000:1,
500:1 in a solution containing 150 mM NaCl and 20 mM MOPS (pH7.2) at 22 °C. After digestion for 6 min, the
digestion was terminated by adding a 10-fold excess of soybean trypsin inhibitor.
Assays of Depolarization-induced Ca2+
Release--
To induce Ca2+ release by T-tubule
depolarization, we employed the K+ to Na+
replacement protocol, which was originally devised in the skinned fiber
system by Lamb and Stephenson (23) and was adopted to our triad system
(24). The T-tubule moiety (1.0 mg/ml) of the triad was first polarized
by incubating in the base solution (150 mM potassium
gluconate, 15 mM NaCl, 20 mM imidazole, pH 6.8)
containing 5.0 mM MgATP, 100-150 µM
CaCl2, and an ATP-regenerating system (2.5 mM
phosphoenolpyruvic acid and 10 units/ml pyruvate kinase) for 10 min.
Then, the T-tubule moiety was depolarized by mixing in a stopped-flow
apparatus (Bio-Logic SFM-4) 30 µl of the solution (solution A)
containing the polarized triads with 120 µl of depolarization solution (solution B) having various ionic compositions to produce various degrees of depolarization (see Table I).
The time course of Ca2+ release was monitored in a stopped
flow apparatus (Bio-Logic SFM-4 with MOS-200 optical system; excitation at 440 nm, emission at 510 nm using an interference filter with 40-nm
bandwidth) using fluo-3 as a Ca2+ indicator as described
previously (14, 20, 25). Six to 10 traces (each representing 1,000 data
points) of the fluo-3 signal were averaged for each experiment.
Spectrometric Monitoring of Depolarization-induced Conformational
Change in the Physiologic E-C Coupling Sites of the RyR--
The
fluorescence change of the MCA that had been incorporated to the
peptide A- or peptide C-binding site of the RyR in a site-specific
fashion (see above) was induced by various degrees of T-tubule
depolarization. The time course of the MCA fluorescence change was
monitored with the stopped-flow fluorometer (Bio-Logic SFM-4 with
MOS-200 optical system: excitation at 368 nm, emission at 455 nm using
an interference filter with 70 nm bandwidth) as described previously
(14, 19). Ten to 15 traces (each representing 1,000 data points) of the
MCA signal were averaged for each experiment.
Assays of Ca2+ Release Induced by the
Voltage-independent Agonists--
To induce Ca2+ release
triggered by several voltage-independent agonists of the RyR as a
control, the microsomes (0.4 mg/ml) were incubated in a solution
containing 0.15 M potassium gluconate, 1 mM
MgATP, 40-50 µM CaCl2, 20 mM
MES, pH 6.8, for 5 min for active Ca2+ loading. Then one
volume of the above solution was mixed with one volume of a release
solution containing 0.15 M potassium gluconate, 5.0 µM fluo-3, 20 mM MES, pH 6.8, and various
agonists (peptide A, polylysine, and caffeine). The time course of SR
Ca2+ release was monitored in a stopped flow apparatus
using fluo-3 as a Ca2+ indicator as described previously
(25). Six to 10 traces (each representing 1,000 data points) of the
fluo-3 signal were averaged for each stopped-flow measurement. Several
such measurements (n = 3-5) were repeated for each
experiment shown in the figure.
Control Assays of the Effect of the Voltage-independent Agonists
on the MCA Fluorescence--
The time courses of fluorescence change
of the protein-bound MCA upon mixing with various RyR agonists were
monitored with the stopped-flow fluorometer as described previously
(25). Ten to 15 traces (each representing 1,000 data points) of the MCA signal were averaged for each experiment.
Calculation of Kinetic Parameters and Statistics--
The time
courses of MCA fluorescence change and Ca2+ release were
fitted by the equation: y = A
(1-exp(
kt)), where A is the maximum amount of
Ca2+ release, k is the rate constant of
Ca2+ release, t is reaction time, and
Ak is the initial rate of Ca2+ release since
(dy/dt)t=0 = A*k. Unpaired t test was employed to
determine the statistical significance.
 |
RESULTS |
Site-specific Fluorescence Labeling of the II-III Loop Peptide
Binding Regions of the RyR--
In our recent studies (12, 14, 20,
24), we incorporated the conformation-sensitive fluorescent probe MCA
into the trans-membrane channel domain using the Ca2+
channel blocker neomycin as a site-directing carrier and monitored conformational changes in the channel domain induced by various types
of RyR agonists. In the present study, we introduced the MCA probe into
the putative II-III loop binding region of the RyR using peptide A and
peptide C as site-directing carriers. For this purpose, the
triad-enriched SR fraction was incubated with the SAED-peptide A or the
SAED-peptide C conjugate (azido-MCA-S-S-peptide A or
azido-MCA-S-S-peptide C) followed by photo-cross linking of the
conjugate with the triad via the azido group. Then peptide A or peptide
C (site-directing carrier) was removed from the cross-linking site by
cleaving the S-S bond of SAED, leaving the MCA that had been covalently
attached to the cross-linked site (details are provided under
"Experimental Procedures").
Fig. 1A depicts Coomassie Blue
staining, Western blot, and MCA fluorescence-labeling patterns of the
electrophoretically separated protein bands of the triad-enriched SR
preparation that has been subjected to the site-directed
MCA labeling by mediation of peptide A or peptide C. Fig. 1A
also contains the set of staining patterns of the sample that was
labeled with MCA first and then digested with calpain II. The
corresponding pictures of the undigested sample (
calpain) and
digested sample (+calpain) are arranged side by side to facilitate the
comparison. As seen in lane 9 (peptide A) and lane
11 (peptide C), the MCA fluorescence is associated almost
exclusively with the 550-kDa band in both cases when the MCA labeling
has taken place by mediation of peptide A and peptide C. The
MCA-labeled 550-kDa band was identified as the RyR protein by
immuno-staining with the RyR-specific polyclonal antibody (lane 3). The result indicates that both peptide A and peptide C have bound specifically to the RyR moiety out of numerous proteins present
in the triad preparation. As shown in Fig. 1B, photolysis of
the mixture of the triads and the peptide-SAED conjugate in the
presence of an excess amount of unmodified peptide (cold
chase experiment) resulted in a considerably reduced amount of MCA
incorporation (for the quantities and statistics, see the legend to
Fig. 1B). This suggests that the peptide-SAED conjugate
bound to the same site as the unmodified peptide bound and that the
sites of the peptide-mediated MCA labeling basically represent the
sites of the peptide binding.

View larger version (53K):
[in this window]
[in a new window]
|
Fig. 1.
A, site-specific labeling of the
RyR moiety with the fluorescent conformational probe MCA by mediation
of peptide A or peptide C. Note that photo-affinity cross-linking of
the triad with the conjugate of SAED with peptide A or peptide C
permitted specific MCA fluorescence labeling almost exclusively at the
RyR out of the many proteins present in the triad preparation.
Digestion of the RyR with calpain II produced two fragments with ~150
and 400 kDa. The 400-kDa fragment corresponds to the segment at the
C-terminal side of the calpain cleavage site as evidenced by its
reactivity with anti-residue 5029 antibody (Ab 5029), whereas the
150-kDa fragment corresponds with the segment at the N-terminal side as
shown by its reactivity with anti-residue 416 antibody (Ab 416). The
MCA incorporated by mediation of peptide A is almost exclusively in the
400-kDa fragment, whereas the MCA incorporated by mediation of peptide
C is almost exclusively in the 150-kDa fragment. The whole set of the
experiment shown in this figure was repeated at least five times for
the reproducible results. B, cold chase experiments
showing the competition of the un-conjugated (cold chase)
peptide A (left panel) and peptide C (right
panel) with the peptide-SAED conjugates. Sample 1 (lanes
1 and 1'), photo-affinity MCA labeling was performed by
mediation of 5 µM peptide A-SAED conjugate. Sample 2 (lanes 2 and 2'), photo-affinity MCA labeling was
performed by mediation of 5 µM peptide A-SAED conjugate
in the presence of 500 µM peptide A. Sample 3 (lanes 3 and 3'), photo-affinity MCA labeling was
performed by mediation of 10 µM peptide C-SAED conjugate.
Sample 4 (lanes 4 and 4'), photo-affinity MCA
labeling was performed by mediation of 10 µM peptide
C-SAED conjugate in the presence of 500 µM peptide C. Lanes 1, 2, 3, and 4,
Coomassie Blue-stained gels. Lanes 1', 2',
3', and 4', fluorescence gels. The density of the
peptide A-mediated MCA fluorescence labeling in the presence of 500 µM peptide A was 23.1 ± 3.5% that of the control
(without cold chase) (n = 4). The density of the
peptide C-mediated MCA fluorescence labeling in the presence of 500 µM peptide C was 31.8 ± 5.2% that of the control
(without cold chase) (n = 4).
|
|
To localize the sites of MCA labeling (i.e. the sites of
binding of peptide A and peptide C) in the primary structure of the RyR, the MCA-labeled RyR was cleaved at the residue 1400 (26) with
calpain II, which produced ~150 and ~400 kDa fragments (Fig. 1A, lane 2). The 150- and 400-kDa fragments must
have originated from the N- and C-terminal segments of the RyR,
respectively, because the former was stained with anti-residue 416 antibody (Fig. 1A, lane 6), but the latter was
stained with anti-residue 5029 antibody (Fig. 1A, lane
8). Interestingly, the MCA fluorescence was found almost
exclusively in the 400-kDa calpain fragment if the MCA labeling was
mediated by peptide A (Fig. 1A, lane 10). If the
MCA labeling was mediated by peptide C, however, the MCA fluorescence
was found almost exclusively in the 150-kDa fragment (Fig.
1A, lane 12).
Tryptic digestion cleaved the RyR more extensively, producing shorter
fragments (Fig. 2). In this figure,
MCA-labeling patterns were compared with Western blot patterns obtained
with various site-specific anti-RyR monoclonal antibodies. In case of
peptide A-mediated labeling (upper panel), after relatively
extensive digestion, the major intensity of MCA fluorescence was
localized in a 160-kDa tryptic sub-fragment. Because this sub-fragment
was stained with anti-residue 1417 antibody (Ab 1417) but not with anti-residue 2727 antibody (Ab 2727), the peptide A-mediated MCA labeling site, i.e. peptide A-binding site, seemed to be
localized in the region of the RyR encompassing residues 1400-2726, as
illustrated at the bottom of Fig. 2. There is an additional lower
molecular mass (145 kDa) tryptic sub-fragment labeled with MCA that
matches approximately with the band intensely stained with anti-residue 416 antibody (Ab 416). We assume that the 145-kDa fluorescent sub-fragment has derived not from the N-terminal 150-kDa calpain fragment but from the 160-kDa (peptide A binding region) tryptic sub-fragment described above for the following reasons. First, the
molecular mass of the Ab 416-stained band (150 kDa) was always higher
than that of the 145-kDa MCA-labeled sub-fragment. Second, not even a
trace of MCA labeling was detected in the 150-kDa N-terminal region of
the RyR, as described in Fig. 1A. The lower panel
of Fig. 2 shows the result of similar site-localization experiments with peptide C-mediated MCA labeling. In this case, the MCA-labeling site was localized in the 150-kDa sub-fragment that was stained with
anti-residue 416 antibody (Ab 416) after a partial tryptic digestion.
After more extensive digestion, the shortest fluorescent sub-fragment
was a 100-kDa subfragment that was stained intensely with Ab 416, indicating that peptide C binds the 100-kDa region of the N-terminal
segment as indicated in the diagram at the bottom of Fig. 2. The above
results suggest that both II-III loop peptides, peptide A and peptide
C, bind exclusively to the RyR moiety out of many proteins present in
the triad preparation. However, peptide A and peptide C introduced the
fluorescence MCA probe to the clearly distinguishable regions of the
RyR. Thus, it is concluded that peptide A and peptide C bind to the RyR
in protein-specific and domain-specific manners. Although it may well
be that the peptide binding domain actually consists of a multiple
number of binding sites distributed in the different places of the
primary structure, to facilitate discussion these distinguished regions
will be called A-site (peptide A-binding site) and C-site (peptide
C-binding site), respectively.

View larger version (55K):
[in this window]
[in a new window]
|
Fig. 2.
Peptide mapping of the MCA-labeling sites
(peptide A- and peptide C-binding sites). To produce shorter
peptide fragments to further localize the labeling sites, the RyR that
had been labeled with MCA by mediation of either peptide A, or peptide
C was digested with trypsin at various trypsin/SR protein ratios (no
digestion (1st lane), 4000:1 (2nd lane), 2000:1
(3rd lane), 1000:1 (4th lane), 500:1 (5th
lane)) at 22 °C. Electrophoretically separated bands on
the 6% SDS gel were transferred to Immobilon-P membrane. The blotted
sample was reacted with various primary antibodies (Ab 416, Ab 1417, Ab
2727, and Ab 5029) overnight at 22 °C followed by the treatment with
alkaline phosphatase-conjugated second antibodies for 3 h and
stained with diaminobenzidine. Correlation of the digestion pattern
with the fluorescence-labeling pattern permitted us to localize the MCA
labeling sites in shorter peptides. In the case of peptide A-mediated
MCA incorporation (upper panel), the shortest recognizable
peptide showing the intense MCA fluorescence was a 160-kDa sub-fragment
that reacted with Ab 1417 antibody but not with Ab 2727. Thus, the
peptide A-mediated MCA incorporation site (i.e. peptide
A-binding site) must be within the region encompassing residue 1400 (calpain cleavage site) and residue 2726 (see the diagram shown at the
bottom). In the case of peptide C-mediated incorporation
(lower panel), the shortest recognizable fluorescent band
was a 100-kDa sub-fragment, which reacted with Ab 416 but not with Ab
1417. This indicates that the peptide C-binding site is in the 100-kDa
segment located at the N-terminal side of the peptide A binding region,
as shown in the diagram. The whole set of experiments shown in this
figure was repeated four times for reproducible results.
|
|
The MCA Probe Attached to the A-site, Not That Attached to the C
Site, Reports T-tubule Depolarization-induced Local Events in the
Coupled Triad--
The MCA-labeled triad preparation by mediation of
either peptide A or peptide C showed almost intact activity of
depolarization-induced Ca2+ release as the unlabeled
preparation, although there was a significant decrease in the rate of
depolarization-induced Ca2+ release; at G9, 60.01 ± 11.9 nmol/mg/s (n = 4) in the MCA-labeled triads (see
Table II) versus 435.8 ± 73.9 nmol/mg/s
(n = 5) in the case of the unlabeled triads
(cf. Ref. 14). Therefore, the labeled triads can serve as a
useful in vitro model of E-C coupling. We examined whether
any of these activators produce appreciable changes in the fluorescence
intensity of the MCA that had been incorporated into either the A or C
site on the RyR in a protein-specific manner. We found that
depolarization of the T-tubule moiety of the triad induced a rapid
increase in the fluorescence intensity of the MCA bound to the A-site
but no appreciable change in the MCA bound to the C-site.
Fig. 3 depicts the time courses of the
increase in the fluorescence intensity of the MCA bound to the A-site
(left panel) and Ca2+ release (right
panel) induced by various degrees of T-tubule depolarization after
the K+-to-Na+ replacement protocol shown in
Table I ("Experimental Procedures"). In the control mixing with no K+-to-Na+
replacement, viz. with no depolarization (G1), there was no
appreciable change in the MCA fluorescence and no induced
Ca2+ release. Upon increasing the degree of T-tubule
depolarization (the degree of depolarization is expressed as the ratio
of (Na+ concentration after mixing)/(the Na+
concentration before mixing), the magnitude of the MCA fluorescence change increased. Concomitantly, the magnitude of induced
Ca2+ release increased in proportion to the increased
magnitude of the MCA fluorescence change. The MCA fluorescence change
was much faster than that of Ca2+ release at all degrees of
T-tubule depolarization tested so far, as seen from Fig. 3 and Table
II. Table II depicts the values of
various kinetic parameters (A, the amplitude; k,
the rate constant; Ak, the initial rate) and the statistic
variations of these values calculated from the data shown in Fig. 3.
This indicates that the MCA fluorescence change represents a local
event occurring in the A-site before Ca2+ release,
suggesting that the former is a causative mechanism for the latter.

View larger version (21K):
[in this window]
[in a new window]
|
Fig. 3.
The time courses of depolarization-induced
changes in the fluorescence intensity of the MCA probe attached to the
peptide A-binding site and the subsequent Ca2+ release at
various magnitudes of depolarization. The T-tubule moiety of the
triad was depolarized to various degrees (G1, G3, G6, G9) by the
K+-to-Na+ replacement protocol (cf.
Table I) at the Ca2+ concentration of 0.3 µM
(the Ca2+ concentration immediately after the stopped-flow
mixing), and the changes in the fluorescence intensity of the MCA
incorporated to the peptide A-binding site and induced Ca2+
release were monitored as described under "Experimental
Procedures." The magnitude of MCA fluorescence change increases with
the magnitude of depolarization in a G-dependent manner. In
parallel to this, the rate and the size of Ca2+ release
also increased. The MCA fluorescence change was much faster than that
of Ca2+ release at each G, indicating that the observed MCA
fluorescence change (conformational change) represents the event that
precedes Ca2+ release. Each MCA fluorescence trace
presented here was obtained by signal-averaging a total of 50-70
traces originated from five experiments. Each Ca2+ release
trace presented here was obtained by signal-averaging a total of 24-40
traces originated from four experiments. The values of kinetic
parameters and the statistic variations calculated from the data of
this figure are shown in Table II. Note that the time scale of MCA
fluorescence change is 10 times faster than that of Ca2+
release.
|
|
View this table:
[in this window]
[in a new window]
|
Table I
Ionic compositions of polarizing solution (A) and depolarizing solution
(B) and those after mixing 1 volume of A and 4 volumes of B (after
A + B) for producing various degrees of depolarization (G values)
by K+-to-Na+ replacement protocol
|
|
View this table:
[in this window]
[in a new window]
|
Table II
Kinetic parameters of MCA fluorescence change (A, the amount of
fluorescence change; k, the rate constant of fluorescence change; Ak,
the initial rate of fluorescence change) and Ca2+ release (A,
the amount of Ca2+ released; k, the rate constant of
Ca2+ release; Ak, the initial rate of Ca2+ release)
induced by various magnitude of T-tubule depolarization (upper part of
the table) and those induced by T-tubule depolarization (G9) in the
presence of nomodipine or ionophores (lower part of the table)
The data were obtained from the experiments shown in Figs. 3 and 5.
Each datum represents the mean ± S.E.
|
|
Fig. 4 depicts the time courses of MCA
fluorescence change at the A-site (left column) and those of
SR Ca2+ release (right column) when the RyR was
stimulated by several DHP receptor-independent agonists (peptide A,
polylysine, and caffeine). Interestingly, none of these agonists
produced any appreciable change in the MCA fluorescence at the A-site
within the time scale of the stopped-flow measurements (0.5 s as
shown). Table III depicts the values of
various kinetic parameters (A, the amplitude; k,
the rate constant; Ak, the initial rate) and the statistic
variations of these values calculated from the data shown in Fig. 4. It
seemed rather puzzling that even peptide A did not produce MCA
fluorescence change. Therefore, we investigated the possibility that
peptide A might be accessible to the A-site in the coupled triad at a
rather slow rate and might produce a slow MCA fluorescence increase by
carrying out hand-mixing experiments. However, it was found that even
at a 5-min time scale 50 µM peptide A produced no
statistically significant MCA fluorescence change (the
F/Fo/t=5
min = 0.35 ± 0.12%, n = 7). Thus, the
rapid MCA fluorescence increase at the A-site observed here does not
represent a local conformational change induced by peptide A. Instead,
the results suggest that T-tubule depolarization induces the
characteristic events in the particular region of the coupled triad
(see "Discussion," Fig. 7 models), and within such region the
A-site and the attached MCA happened to be located.

View larger version (19K):
[in this window]
[in a new window]
|
Fig. 4.
Various agonists that activate the RyR by
direct stimulation produce Ca2+ release without producing
the fluorescence change of the MCA attached to the peptide A-binding
site. The Ca2+-loaded triad vesicles were mixed with
various voltage-independent agonists such as 3 mM caffeine,
100 nM polylysine, and 50 µM peptide A. These
agonists induce a large Ca2+ release but produce no
appreciable change in the MCA fluorescence, indicating that the MCA
labeling site (i.e. peptide A-binding site) is in the domain
outside of the agonist binding-channel activation pathways. The values
of kinetic parameters and the statistic variations calculated from the
data of this figure are shown in Table III.
|
|
View this table:
[in this window]
[in a new window]
|
Table III
Kinetic parameters of MCA fluorescence change (A, the amount of
fluorescence change; k, the rate constant of fluorescence change; Ak,
the initial rate of fluorescence change) and Ca2+ release (A,
the amount of Ca2+ released; k, the rate constant of
Ca2+ release; Ak, the initial rate of Ca2+ release)
induced by T-tubule depolarization and various voltage-independent
agonists: 3 mM caffeine, 100 nM polylysine, and
50 µM peptide A
The data were obtained from the experiments shown in Figs. 3 and 4.
Each datum represents the mean ± S.E.
|
|
The experiment shown in Fig.
5 further supports the above notion. In
this experiment, the triads were incubated in the priming solution
containing nimodipine (antagonist of the DHP receptor at 1 µM, a sufficient concentration to uncouple the DHP
receptor-to-RyR communication (27)) and monensin/valinomycin mixture
(an agent to prevent the formation of the trans-T-tubule membrane
Na+/K+ gradient) and then mixed with the
depolarization solution (G9). As seen, both of these agents almost
completely abolished both MCA fluorescence change and subsequent
Ca2+ release (the values of various kinetic parameters and
the statistic variations are shown in Table II). This indicates that
the observed MCA fluorescence change (in the A-site domain) is under
the control of the DHP receptor. It should be noted that neither of
these agents produced any appreciable effects on Ca2+
release induced by the voltage-independent agonists such as peptide A,
polylysine, and caffeine.

View larger version (18K):
[in this window]
[in a new window]
|
Fig. 5.
There was no MCA fluorescence change if the
depolarization procedure took place in the presence of nimodipine or in
the presence of ionophores (monensin and valinomycin). 1 µM nimodipine (upper panel) or the mixture of
10 µM valinomycin and 10 µM monensin
(lower panel) prevented the MCA fluorescence change from
occurring even when a maximal degree of ionic replacement (G9) was
applied. Consequently, the subsequent Ca2+ release was
almost completely blocked. The values of kinetic parameters and the
statistic variations calculated from the data of this figure are shown
in the bottom part of Table II.
|
|
In the experiment shown in Fig. 6 and
Table IV, we carried out the same type of
depolarization-induced Ca2+ release experiment as above
using the triad preparation in which MCA was labeled to the C-site. As
seen, T-tubule depolarization induced Ca2+ release but
produced no appreciable change in the fluorescence intensity of the MCA
that had been attached to the C-site. The values of kinetic parameters
and the statistic variations are shown in the table attached to the
legend to Fig. 6. Overall, the above results suggest that the
postulated depolarization-induced characteristic events are localized
in the region where the peptide A-mediated MCA labeling has taken
place.

View larger version (13K):
[in this window]
[in a new window]
|
Fig. 6.
T-tubule depolarization produced no
appreciable change in the fluorescence intensity of the MCA
incorporated to the peptide C-binding site of the RyR. The
site-specific MCA incorporation into the RyR moiety of the triad was
performed by mediation of peptide C as a site-directing carrier, and
T-tubule depolarization (G9) was performed as described under
"Experimental Procedures." The values of kinetic parameters and the
statistic variations calculated from the data of this figure are shown
in Table IV.
|
|
View this table:
[in this window]
[in a new window]
|
Table IV
Kinetic parameters of fluorescence change of MCA attached to the C-site
(A, the amount of fluorescence change; k, the rate constant of
fluorescence change; Ak, the initial rate of fluorescence change) and
Ca2+ release (A, the amount of Ca2+ released;
k, the rate constant of Ca2+ release; Ak, the initial rate
of Ca2+ release) induced by T-tubule depolarization (G9).
The data were obtained from the experiments shown in Fig. 6. Each datum
represents the mean ± S.E.
|
|
 |
DISCUSSION |
In this study, we addressed the two key questions as to
(a) whether peptide A and peptide C bind to the RyR in a
protein- and site-specific manner and (b) whether the
fluorescent probe that is attached to the peptide-binding sites can
report the local events that are relevant to the physiological coupling
between the DHP receptor and the RyR. The site-directed fluorescence
probe-labeling technique we used in this study (original description,
Ref. 21) involves the use of a hetero-bifunctional cleavable
photo-affinity cross-linking reagent, SAED, with such a structure,
(azido group)-(fluorescent adduct MCA)-S-S-(succinimidyl). Upon forming
the conjugate of a selected ligand via the reaction of its reactive
amino group with succinimidyl of SAED, the ligand delivers the
conjugate to its binding site in a site-directed fashion serving as a
site-directing carrier. Photo-cross-linking of the conjugate via the
azido group of SAED followed by removal of the ligand moiety by
cleaving the S-S bond under reducing conditions permits site-specific
covalent labeling of the ligand-binding site with MCA. In our recent
studies, we used neomycin (a blocker of the RyR Ca2+
channel, which is known to bind to the trans-membrane channel domain,
Ref. 28) as the site-directing carrier to introduce MCA to the channel
domain and investigated conformational changes occurring in the channel
domain upon activation of the channel by various types of agonists (14,
20, 25). In the case when the site of the ligand binding has not yet
been characterized as in the present case with the II-III loop
peptides, the site-directed labeling technique provides a powerful tool
to identify and characterize the site of peptide binding. Furthermore,
if the probe is introduced successfully in the specific site or the
specific region as in the present case, the protein-bound probe can
serve as a reporter of the local events occurring during E-C coupling.
Thus, the application of this technique in the present study has
permitted us to investigate both key questions a and
b outlined above.
With regard to the specificity of peptide binding, the fact that
specific fluorescence labeling of the RyR could be achieved by using
peptide A or peptide C as a site-directing carrier clearly indicates
that both peptide A and peptide C are the RyR-specific ligands. The
present results also suggest that peptide A and peptide C bind to the
specific domains; hence, their binding is not only protein-specific but
also domain-specific. Thus, the chief fluorescence labeling of the
peptide A-binding site (A-site) occurred in the 160-kDa region located
at the C-terminal side of the primary calpain II cleavage site at
residue 1400 (26), whereas the chief fluorescence labeling of the
peptide C-binding site (C-site) occurred in the 100-kDa segment located
at the opposite side (i.e. N-terminal side) of the primary
calpain cleavage site. We propose that in the quaternary structure the
A-site and the C-site are in a close apposition to each other for
several reasons. First, according to our preliminary study (29), the
fluorescence energy transfer could be detected between the donor and
acceptor placed at the A- and C-sites, respectively. Second, several
different regions of the RyR have been identified as the II-III loop
binding domains in the literature. Using deletion strategy, Yamazawa
et al. (30) identified the residue-1303-1406 (D2) region as
a critical region. The chimera approach by Nakai et al. (31)
suggest that the critical region is in a rather long 1635-2636
stretch. On the other hand, the II-III loop affinity column assay by
Leong and MacLennan (32) suggests a short 1076-1112 segment. These
findings are consistent with the view that the putative a II-III
loop-binding core is constructed by multiple segments that are
scattered in a relatively broad range of the primary structure (29).
Third, we pay a particular attention to an interesting analogy of our
present results to the structure of the so-called inositol
1,4,5-trisphosphate (IP3) binding core located in the
N-terminal region of the IP3 receptor, where the basic
residues critical for IP3 binding are positioned at both
sides of the site that is highly susceptive to proteolytic cleavage
(33).
The most important aspect of this study is the finding that
depolarization of the T-tubule moiety of the triad preparation produced
a rapid increase of the fluorescence intensity of the MCA attached to
the A-site. The chemical depolarization protocol with various degrees
of K+-to-Na+ replacement permits generation of
various degrees of depolarization in the T-tubule moiety of the triad
as described previously (23, 25). As shown here, upon increasing the
magnitude of T-tubule depolarization, the magnitude of the MCA
fluorescence change increased, and the magnitude of the induced
Ca2+ release increased in a proportionate fashion. The MCA
fluorescence change was much faster than Ca2+ release,
suggesting that the local conformational change in the peptide
A-binding domain reported by the attached MCA probe represents a
causative and prerequisite mechanism for the Ca2+ channel
activation. The observed MCA fluorescence signal and the induced
Ca2+ release are in fact mediated by the voltage change in
the T-tubule moiety and by the DHP receptor voltage sensor, as
evidenced by the facts that dissipation of the
Na+/K+ gradient across the T-tubule membrane by
the monensin/valinomycin mixture and the antagonist of the DHP receptor
nimodipine inhibited both MCA fluorescence change and subsequent
Ca2+ release. In further support of this notion, the MCA
signal was produced in a Ca2+-independent fashion (data not
shown) like depolarization-induced contraction and Ca2+
release (21, 34, 35) but unlike other chemical and pharmacological agonists of the RyR, most of which have a stringent Ca2+ requirement.
In evaluation of the physiological significance of the above data,
critically important is the fact that the MCA fluorescence exchange at
the A-site can be seen in response solely to the one type of activation
signal, i.e. T-tubule depolarization. Other voltage-independent agonists such as peptide A, polylysine, and caffeine induced Ca2+ release but without producing the MCA
fluorescence change. This is in a sharp contrast to the results of the
experiments with the triad preparation in which MCA was attached to the
trans-membrane channel domain by mediation of neomycin, where all types
of agonists we tested produced the MCA fluorescence change (see Table
V). Presumably, the conformational change
that was reported by the MCA at the channel domain represents the
gating behavior of the channel common to various types of agonists of
the RyR. Furthermore, T-tubule depolarization produced the fluorescence
change only when the MCA probe was placed at the A-site but did not if
the MCA was at the C-site.
View this table:
[in this window]
[in a new window]
|
Table V
Comparison of the types of responses of the MCA attached to the peptide
A binding site and the MCA attached to the neomycin binding site
located at the trans-membrane channel domain
+, appreciable fluorescence change; , no appreciable change.
|
|
In attempts to account for the present results, we postulate two
alternative models as shown in Fig. 7,
models a and b. Model a assumes that upon
T-tubule depolarization a portion of the DHP receptor comes very close
to the RyR, forming a highly hydrophobic DHP receptor/RyR interface. If
the A-site is located within such an interface region, the fluorescence
intensity of the attached MCA will show a rapid increase upon forming
such a hydrophobic DHP receptor/RyR interface. Although peptide A is
capable of delivering the MCA probe to the A-site and the binding of
peptide A to this site induces SR Ca2+ release, it is
incapable of inducing the DHP receptor/RyR contact, which is a specific
event produced by the DHP receptor voltage-sensing. Although we are
inclined to model a, we cannot exclude an alternative model
shown in model b. Namely, T-tubule depolarization produces characteristic conformational change (e.g. internalization
of the attached MCA probe) in some region of the RyR, which is
not necessarily in the DHP receptor/RyR interacting region. Because the
blocking of the DHP receptor-to-RyR communication results in the
inhibition of the T-tubule depolarization-induced characteristic events
regardless of the location of the A-site (either the DHP receptor/RyR
interface or in the cytoplasmic domain of the RyR), it is difficult to
decide either model by kinetic experiments alone. We should probably
await for the information about the exact locations of the A-site and
of the DHP receptor-interacting region within the three-dimensional
image of the RyR. At any rate, the present finding that the T-tubule
depolarization-induced characteristic events take place in the region
where the A-site is located suggests that peptide A can serve as a
useful tool at least for introducing the conformational probe to the
physiologically important domain.

View larger version (15K):
[in this window]
[in a new window]
|
Fig. 7.
Hypothetical models illustrating that
depolarization in the T-tubule moiety of the triad induces local events
that cause a rapid increase in the hydrophobicity of the environment in
the vicinity of the MCA attached to the RyR. We tentatively
propose that such an event would take place in the DHP receptor/RyR
interface as shown in model a. However, it may well be that such an
event takes place in the cytoplasmic domain of the RyR as shown in
model b.
|
|
 |
ACKNOWLEDGEMENTS |
We thank Dr. Graham D. Lamb for comments on
this work and Dr. Renne C. Lu, Dr. Paul Leavis, Gina Pagani, and
Elizabeth Gowell for help in the synthesis and purification of the
peptides. We also thank Drs. Susan L. Hamilton, Andrew R. Marks, and
Kevin P. Campbell for their generous supply of anti-RyR antibodies.
 |
FOOTNOTES |
*
This work was supported by National Institutes of Health
Grant AR 16922.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
¶
To whom correspondence should be addressed: Boston
Biomedical Research Inst., 64 Grove St., Watertown, MA 02472. Tel.:
617-658-7774; Fax: 617-972-1761; E-mail: ikemoto@bbri.org.
Published, JBC Papers in Press, October 26, 2001, DOI 10.1074/jbc.M102347200
 |
ABBREVIATIONS |
The abbreviations used are:
DHP, dihydropyridine;
BAPTA, 1,2-bis(o-aminophenoxy)ethane-N,
N,N',N'-tetraacetic acid;
E-C
coupling, excitation-contraction coupling;
MCA, methyl coumarin
acetamido;
MES, 2-(N-morpholino)ethanesulfonic acid;
MOPS, 3-(N-morpholino) propanesulfonic acid;
RyR, ryanodine
receptor;
SAED, sulfosuccinimidyl
2-[7-azido-4-methyl-coumarin-3-acetamido]
ethyl-1,3'-dithiopropionate;
SR, sarcoplasmic reticulum;
Ab, antibody.
 |
REFERENCES |
| 1.
|
Tanabe, T.,
Beam, K. G.,
Powell, J. A.,
and Numa, S.
(1988)
Nature
336,
134-139
|
| 2.
|
Tanabe, T.,
Beam, K. G.,
Adams, B. A.,
Niidome, T.,
and Numa, S.
(1990)
Nature
346,
567-569
|
| 3.
|
Nakai, J.,
Tanabe, T.,
Konno, T.,
Adams, B.,
and Beam, K. G.
(1998)
J. Biol. Chem.
273,
24983-24986
|
| 4.
|
Grabner, M.,
Dirksen, R. T.,
Suda, N.,
and Beam, K. G.
(1999)
J.
Biol. Chem.
274,
21913-21919
|
| 5.
|
Lu, X., Xu, L.,
and Meissner, G.
(1994)
J. Biol. Chem.
269,
6511-6516
|
| 6.
|
Lu, X., Xu, L.,
and Meissner, G.
(1995)
Biophys. J.
68,
372 (abstr.)
|
| 7.
|
El-Hayek, R.,
Antoniu, B.,
Wang, J.,
Hamilton, S. L.,
and Ikemoto, N.
(1995)
J. Biol. Chem.
270,
22116-22118
|
| 8.
|
Dulhunty, A. F.,
Laver, D. R.,
Gallant, E. M.,
Casarotto, M. G.,
Pace, S. M.,
and Curtis, S.
(1999)
Biophys. J.
77,
189-203
|
| 9.
|
Casarotto, M. G.,
Gibson, F.,
Pace, S. M.,
Curtis, S. M.,
Mulcair, M.,
and Dulhunty, A. F.
(2000)
J. Biol. Chem.
275,
11631-11637
|
| 10.
|
Gurrolla, G. B.,
Arevalo, C.,
Sreekumar, R.,
Lokuta, A. J.,
Walker, J. W.,
and Valdivia, H. H.
(1999)
J. Biol. Chem.
274,
7879-7886
|
| 11.
|
Zhu, X.,
Gurrola, G.,
Jiang, M. T.,
Walker, J. W.,
and Valdivia, H. H.
(1999)
FEBS Lett.
450,
221-226
|
| 12.
|
El-Hayek, R.,
and Ikemoto, N.
(1998)
Biochemistry
37,
7015-7020
|
| 13.
|
Stange, M.,
Tripathy, A.,
and Meissner, G.
(2001)
Biophys. J.
81,
1419-1429
|
| 14.
|
Saiki, Y., El-,
Hayek, R.,
and Ikemoto, N.
(1999)
J.
Biol. Chem.
274,
7825-7832
|
| 15.
|
Lamb, G. D., El-,
Hayek, R.,
Ikemoto, N.,
and Stephenson, D. G.
(2000)
Am. J. Physiol. Cell Physiol.
279,
891-905
|
| 16.
|
Ikemoto, N.,
and El-Hayek, R.
(1998)
in
Mechanisms of Work Production and Work Absorption in Muscle
(Sugi, H.
, and Pollack, G. H., eds)
, pp. 199-207, Plenum Press, New York
|
| 17.
|
Proenza, C.,
Wilkens, C. M.,
and Beam, K. G.
(2000)
J.
Biol. Chem.
275,
29935-29937
|
| 18.
|
Wilkens, C. M.,
Kasielke, N.,
Flucher, B. E.,
Beam, K. G.,
and Grabner, M.
(2001)
Proc. Natl. Acad. Sci. U. S. A.
98,
5892-5897
|
| 19.
|
Ahern, C. A.,
Arikkath, J.,
Vallejo, P.,
Gurnett, C. A.,
Powers, P. A.,
Campbell, K. P.,
and Coronado, R.
(2001)
Proc. Natl. Acad. Sci. U. S. A.
98,
6935-6940
|
| 20.
|
Yano, M., El-,
Hayek, R.,
and Ikemoto, N.
(1995)
J. Biol. Chem.
270,
3017-3021
|
| 21.
|
Kang, J. J.,
Tarcsafalvi, A.,
Carlos, A. D.,
Fujimoto, E.,
Shahrokh, Z.,
Thevenin, B. J.,
Shohet, S. B.,
and Ikemoto, N.
(1992)
Biochemistry
31,
3288-3293
|
| 22.
|
Ikemoto, N.,
Kim, D. H.,
and Antoniu, B.
(1988)
Methods Enzymol.
157,
469-480
|
| 23.
|
Lamb, G. D.,
and Stephenson, D. G.
(1990)
J. Physiol.
423,
495-517
|
| 24.
|
Ikemoto, N.,
Yano, M., El-,
Hayek, R.,
Antoniu, B.,
and Morii, M.
(1994)
Biochemistry
33,
10961-10968
|
| 25.
|
El-Hayek, R.,
Yano, M.,
and Ikemoto, N.
(1995)
J. Biol. Chem.
270,
15634-15638
|
| 26.
|
Wu, Y.,
Aghdasi, B.,
Dou, S. J.,
Zhang, J. Z.,
Liu, S. Q.,
and Hamilton, S. L.
(1997)
J. Biol. Chem.
272,
25051-25061
|
| 27.
|
Rios, E.,
and Brum, G.
(1987)
Nature
325,
717-720
|
| 28.
|
Wang, J. P.,
Needleman, D. H.,
Seryshev, A. B.,
Aghdasi, B.,
Slavik, K. J.,
Liu, S. Q.,
Pedersen, S. E.,
and Hamilton, S. L.
(1996)
J. Biol. Chem.
271,
8387-8393
|
| 29.
|
Yamamoto, T., El-,
Hayek, R.,
and Ikemoto, N.
(2000)
Biophys. J.
79,
428 (Abstr. 2525-Pos)
|
| 30.
|
Yamazawa, T.,
Takeshima, H.,
Shimuta, M.,
and Iino, M.
(1997)
J. Biol. Chem.
272,
8161-8164
|
| 31.
|
Nakai, J.,
Sekiguchi, N.,
Rando, T. A.,
Allen, P. D.,
and Beam, K. G.
(1998)
J. Biol. Chem.
273,
13403-13406
|
| 32.
|
Leong, P.,
and MacLennan, D. H.
(1998)
J. Biol. Chem.
273,
29958-29964
|
| 33.
|
Yoshikawa, F.,
Iwasaki, H.,
Michikawa, T.,
Furuichi, T.,
and Mikoshiba, K.
(1999)
J. Biol. Chem.
274,
328-334
|
| 34.
|
Nakajima, Y.,
and Endo, M.
(1973)
Nat. New Biol.
246,
216-218
|
| 35.
|
Stephenson, E. W.
(1981)
Am. J. Physiol.
240,
C1-C19
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
Q. Zhou, Q.-L. Wang, X. Meng, Y. Shu, T. Jiang, T. Wagenknecht, C.-C. Yin, S.-F. Sui, and Z. Liu
Structural and Functional Characterization of Ryanodine Receptor-Natrin Toxin Interaction
Biophys. J.,
November 1, 2008;
95(9):
4289 - 4299.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Paul-Pletzer, T. Yamamoto, M. B. Bhat, J. Ma, N. Ikemoto, L. S. Jimenez, H. Morimoto, P. G. Williams, and J. Parness
Identification of a Dantrolene-binding Sequence on the Skeletal Muscle Ryanodine Receptor
J. Biol. Chem.,
September 13, 2002;
277(38):
34918 - 34923.
[Abstract]
[Full Text]
[PDF]
|
 |
|